a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FTTEX | 11.71 | -0.08 | -0.68% |
Fidelity Advisor Total Intl Equity M | |||
AVCNX | 18.53 | -0.15 | -0.80% |
Avantis® U.S. Small Cap Value G | |||
VMGIX | 101.15 | -0.94 | -0.92% |
Vanguard Mid-Cap Growth Index Investor | |||
OGIIX | 51.28 | -0.48 | -0.93% |
Invesco Global Opportunities R6 | |||
BUFOX | 16.67 | -0.35 | -2.06% |
Buffalo Early Stage Growth Fd |
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.
Ticker / NAME | Correlation To HRMY | 1D Price Change % | ||
---|---|---|---|---|
HRMY | 100% | +0.65% | ||
SNBIF - HRMY | 52% Loosely correlated | N/A | ||
SAGE - HRMY | 43% Loosely correlated | -5.03% | ||
ANAB - HRMY | 42% Loosely correlated | -5.80% | ||
RVNC - HRMY | 39% Loosely correlated | -3.25% | ||
GYRE - HRMY | 38% Loosely correlated | -5.20% | ||
More |